Source - SMW
EKF Diagnostics Holdings expects adjusted EBITDA to comfortably exceed forecasts. 

The company said revenues for the year ended 31 Dec were in line with expectations and net cash stood at £6.8m.

The company also announced that it intends to spin-out its sTNFR biomarker technology into a separate entity to enable it to exploit opportunities to realise value from this technology, which having been fully impaired and has a current carrying value of nil. 

sTNFR1/2 (Soluble Tumour Necrosis Factor Receptors 1 and 2) are novel biomarkers used to identify type 1 and type 2 diabetes patients at highest risk of progressive Diabetic Kidney Disease (DKD) potentially leading to End Stage Renal Disease (ESRD). 

EKF said the directors intended to establish a joint venture to develop sTNFR as a routine test for predicting the progression of diabetic patients to ESRD and will make further announcements at the appropriate time.  


At 9:03am: (LON:EKF) EKF Diagnostics Holdings PLC share price was +0.45p at 26.95p